Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04430530 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04430530 · ClinicalTrials.gov record · last posted 2026-08-24

4SCAR-T Therapy Post CD19-targeted Immunotherapy

Name: 4SCAR-T Therapy Post CD19-targeted Immunotherapy — clinical trial record (NCT04430530)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusTerminated

PhasePhase 1/2

SponsorShenzhen Geno-Immune Medical Institute

Started2026-06-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells (4SCAR-T) targeting CD19-negative B-ALL that express alternative surface antigens such as CD22, CD10, CD20, CD38, and CD123, as many patients relapse after anti-CD19 immunotherapy. Clinical response and optiminzation of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

Protocol amendment history 3 changes detected by DataLookout

2026-08-25

Trial terminated

2026-08-25

Primary completion moved earlier: 2029-12-31 → 2026-07-01

2026-08-25

Completion moved earlier: 2030-12-31 → 2026-07-31

Trial Details

NCT Number	NCT04430530
Lead Sponsor	Shenzhen Geno-Immune Medical Institute
Conditions	CD19 Negative B-cell Malignancies
Enrollment	100 participants
Start Date	2026-06-01
Primary Completion	2026-07-01 (estimated)
Study Completion	2026-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-24